Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism


https://www.nejm.org/doi/full/10.1056/NEJMoa1711948


Authors’ Conclusions: “Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding. The rate of recurrent venous thromboembolism was lower but the rate of major bleeding was higher with edoxaban than with dalteparin.”


SGEM: Our conclusion would have been “oral edoxaban had a higher rate of clinically relevant bleeding compared to dalteparin, was noninferior with respect to recurrent VTE and no statistically significant different was observed in all-cause mortality and event-free survival.”


- Visual Abstract by hellomynameisDrKirsty

@KirstyChallen


#Edoxaban #Cancer #VenousThromboembolism #VTE #EBM #VisualAbstract #DVT #PE